209 related articles for article (PubMed ID: 14599971)
1. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
[TBL] [Abstract][Full Text] [Related]
4. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
6. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
Kawata S; Yamasaki E; Nagase T; Inui Y; Ito N; Matsuda Y; Inada M; Tamura S; Noda S; Imai Y; Matsuzawa Y
Br J Cancer; 2001 Apr; 84(7):886-91. PubMed ID: 11286466
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
[TBL] [Abstract][Full Text] [Related]
11. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
13. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
Treiber G; Röcken C; Wex T; Malfertheiner P
Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
[TBL] [Abstract][Full Text] [Related]
14. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Zieren HU; Jacobi CA; Müller JM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma.
Han GH; Yin ZX; Meng XJ; He CY; Zhang HB; Sun AH; Wu KC; Ding J; Fan DM
Chin J Dig Dis; 2006; 7(1):45-8. PubMed ID: 16412037
[TBL] [Abstract][Full Text] [Related]
17. [Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
Masutani S; Shimizu J; Tatsuta M; Masuda F; Imamura H; Ishida H; Furukawa H; Tomotsu K; Yura M; Obana T; Kitamura S; Saeki N; Inoue Y; Takamura M; Ohnishi H
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1579-82. PubMed ID: 14619468
[TBL] [Abstract][Full Text] [Related]
18. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
20. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Jang JW; Bae SH; Choi JY; Oh HJ; Kim MS; Lee SY; Kim CW; Chang UI; Nam SW; Cha SB; Lee YJ; Chun HJ; Choi BG; Byun JY; Yoon SK
Cancer Chemother Pharmacol; 2007 Jan; 59(1):9-15. PubMed ID: 16614848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]